Company: IMNN
Filing Date: 2025-07-22
Form Type: 424B5
Source: 0001641172-25-020519
Chunk: 0

Company: Imunon, Inc.
Filing Date: 2025-07-22
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-279425

PROSPECTUS SUPPLEMENT NO. 2

(to Prospectus dated May 22, 2024 and

Prospectus Supplement dated September 3, 2024)

<div align='center'>IMUNON, INC.

Up to $10,000,000 of Common Stock</div>

This prospectus supplement amends and supplements the information in the prospectus supplement, dated September 3, 2024 (the “ATM Prospectus Supplement”), to the accompanying base prospectus, dated May 22, 2024 (the “Base Prospectus” and, collectively with the ATM Prospectus Supplement, the “Prospectus”) filed as part of our registration statement on Form S-3 (File No. 333-279425) (the “Registration Statement”), relating to the offer, issuance and sale of shares of our common stock, par value $0.01 per share (“Common Stock”), from time to time pursuant to the terms of an At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales Agreement”), by and between us and H.C. Wainwright & Co., LLC, as sales agent or principal (“Wainwright” or the “sales agent”). Through the date hereof, we have sold an aggregate of $1,815,267 of shares of our Common Stock through the sales agent under the Sales Agreement. This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements thereto.

We are filing this prospectus supplement to amend
and supplement the Prospectus to increase the aggregate amount we intend to sell pursuant to the Sales Agreement. As of the date of this
prospectus supplement, we are offering up to an aggregate of $10,000,000 of our Common Stock for sale under the Sales Agreement, which
includes $5,500,000 that was originally authorized pursuant to the ATM Prospectus Supplement and an additional $4,500,000 pursuant to
this prospect